1. Home
  2. CRK vs NUVL Comparison

CRK vs NUVL Comparison

Compare CRK & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Comstock Resources Inc.

CRK

Comstock Resources Inc.

HOLD

Current Price

$21.03

Market Cap

6.9B

Sector

Energy

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$102.43

Market Cap

7.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRK
NUVL
Founded
1983
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.9B
7.8B
IPO Year
1995
2021

Fundamental Metrics

Financial Performance
Metric
CRK
NUVL
Price
$21.03
$102.43
Analyst Decision
Hold
Strong Buy
Analyst Count
10
16
Target Price
$22.30
$134.13
AVG Volume (30 Days)
2.0M
455.9K
Earning Date
04-29-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
288.16
N/A
EPS
1.43
N/A
Revenue
$555,231,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$17.48
$1,165.56
P/E Ratio
$15.32
N/A
Revenue Growth
32.11
N/A
52 Week Low
$14.65
$55.54
52 Week High
$31.17
$113.02

Technical Indicators

Market Signals
Indicator
CRK
NUVL
Relative Strength Index (RSI) 49.57 57.62
Support Level $20.35 $101.37
Resistance Level $22.07 $107.13
Average True Range (ATR) 1.25 3.44
MACD 0.13 0.38
Stochastic Oscillator 38.26 90.59

Price Performance

Historical Comparison
CRK
NUVL

About CRK Comstock Resources Inc.

Comstock Resources Inc is an independent natural gas producer operating in the Haynesville shale, a natural gas basin located in North Louisiana and East Texas with superior economics given its geographical proximity to the Gulf Coast natural gas markets. The Company operates in one business segment, the exploration and production of North American natural gas and oil. It is engaged in the acquisition, development, production, and exploration of oil and natural gas. The company's oil and gas operations are concentrated in Louisiana and Texas.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: